Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).

Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, Seong SJ, Kim TJ, Kim JW, Kim SM, Bae DS, Nam JH.

Eur J Cancer. 2013 Mar;49(4):868-74. doi: 10.1016/j.ejca.2012.09.017. Epub 2012 Oct 13.

PMID:
23072814
2.

Hormonal therapy for women with stage IA endometrial cancer of all grades.

Park JY, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, Kim YT, Bae DS, Nam JH.

Obstet Gynecol. 2013 Jul;122(1):7-14. doi: 10.1097/AOG.0b013e3182964ce3.

PMID:
23743459
3.

Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium.

Park H, Seok JM, Yoon BS, Seong SJ, Kim JY, Shim JY, Park CT.

Arch Gynecol Obstet. 2012 Feb;285(2):473-8. doi: 10.1007/s00404-011-1959-x. Epub 2011 Jun 25.

PMID:
21706284
4.

Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.

Simpson AN, Feigenberg T, Clarke BA, Gien LT, Ismiil N, Laframboise S, Massey C, Ferguson SE.

Gynecol Oncol. 2014 May;133(2):229-33. doi: 10.1016/j.ygyno.2014.02.020. Epub 2014 Feb 19.

PMID:
24561246
5.

Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.

Park JY, Lee SH, Seong SJ, Kim DY, Kim TJ, Kim JW, Kim JH, Kim YM, Kim YT, Bae DS, Nam JH.

Gynecol Oncol. 2013 Apr;129(1):7-11. doi: 10.1016/j.ygyno.2012.12.037. Epub 2012 Dec 30.

PMID:
23283299
6.

Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer.

Park JY, Seong SJ, Kim TJ, Kim JW, Kim SM, Bae DS, Nam JH.

Obstet Gynecol. 2013 Jan;121(1):136-42. doi: http://10.1097/AOG.0b013e31827a0643.

PMID:
23262938
7.

Fertility-preserving treatment in young women with endometrial adenocarcinoma: a long-term cohort study.

Wang CJ, Chao A, Yang LY, Hsueh S, Huang YT, Chou HH, Chang TC, Lai CH.

Int J Gynecol Cancer. 2014 May;24(4):718-28. doi: 10.1097/IGC.0000000000000098.

PMID:
24577149
8.

Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.

Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, Shim JU, Mok JE, Kim TJ.

Int J Gynecol Cancer. 2009 Aug;19(6):1068-73. doi: 10.1111/IGC.0b013e3181aae1fb.

PMID:
19820370
9.

Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.

Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T.

Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Epub 2014 Aug 14. Review.

PMID:
25118836
10.

Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate.

Nomura H, Sugiyama Y, Tanigawa T, Matoda M, Kanao H, Kondo E, Takeshima N.

Arch Gynecol Obstet. 2016 Jan;293(1):177-81. doi: 10.1007/s00404-015-3824-9. Epub 2015 Jul 26.

PMID:
26209972
12.

Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.

De Marzi P, Bergamini A, Luchini S, Petrone M, Taccagni GL, Mangili G, Colombo G, Candiani M.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(7):1178-82. doi: 10.1016/j.jmig.2015.06.004. Epub 2015 Jun 16.

PMID:
26092080
13.

Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.

Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT.

J Clin Oncol. 1999 Jun;17(6):1736-44.

PMID:
10561210
14.

Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.

Gunderson CC, Fader AN, Carson KA, Bristow RE.

Gynecol Oncol. 2012 May;125(2):477-82. doi: 10.1016/j.ygyno.2012.01.003. Epub 2012 Jan 11. Review.

PMID:
22245711
15.

[Conservative treatment of endometrial cancer as a way to preserve fertility. Five-year experience at Instituto Nacional de Perinatilogía Isidro Espinoza de los Reyes].

Arteaga Gómez AC, Castellanos Barroso G, Márquez Acosta G.

Ginecol Obstet Mex. 2012 Jun;80(6):394-9. Spanish.

PMID:
22826967
16.

Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.

Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T, Hatae M, Kodama S, Saito T, Terakawa N, Yaegashi N, Hiura M, Sakamoto A, Tsuda H, Fukunaga M, Kamura T.

J Clin Oncol. 2007 Jul 1;25(19):2798-803.

17.

An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.

Gadducci A, Cosio S, Fanucchi A, Cristofani R, Genazzani AR.

Anticancer Res. 2000 May-Jun;20(3B):1977-84.

PMID:
10928137
18.

Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer.

Yang YC, Wu CC, Chen CP, Chang CL, Wang KL.

Gynecol Oncol. 2005 Nov;99(2):287-93. Epub 2005 Jul 26.

PMID:
16051341
19.

A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women.

Shan BE, Ren YL, Sun JM, Tu XY, Jiang ZX, Ju XZ, Zang RY, Wang HY.

Arch Gynecol Obstet. 2013 Nov;288(5):1115-23. doi: 10.1007/s00404-013-2826-8. Epub 2013 May 5.

PMID:
23644919
20.

Conservative treatment of early endometrial cancer: preliminary results of a pilot study.

Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M, Greggi S.

Gynecol Oncol. 2011 Jan;120(1):43-6. doi: 10.1016/j.ygyno.2010.10.004. Epub 2010 Oct 30.

PMID:
21040953
Items per page

Supplemental Content

Write to the Help Desk